353235-95-7

Upstream product

• 353235-94-6 N-(t-butoxycarbonyl)-N-(2-(4-iodophenyl)ethyl)-N-(methylsulfonyl)amine 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 64-04-0 phenethylamine 
• 33893-36-6 N-(methylsulfonyl)(2-phenylethyl)amine 
• 353235-93-5 N-(2-(4-iodophenyl)ethyl)-N-(methylsulfonyl)amine 

Downstream Products

• 375345-95-2 {(2R)-2-[4-(4-{2-[(methylsulfonyl)amino]ethyl}phenyl)phenyl]-propyl}[(methylethyl)sulfonyl]amine 
• 516491-32-0 N,N'-([1,1'-biphenyl]-4,4'-diyldi-2,1-ethanediyl)-bis-methanesulfonamide 
• 375346-00-2 [4-[2-[(methylsulfonyl)amino]ethyl]phenyl]boronic acid 
• 344462-93-7 N-carbamic acid tert-butyl ester-N-methanesulfonamide-N-phenethyl-4-boronic acid 
• 375345-99-6 N-[2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-phenyl]ethyl]methanesulfonamide 

Relevant academic research and scientific papers

HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF

The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula (I) as defined in the specification. The invention is also directed to compositions containing and uses of

Potentiators of glutamate receptors

The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.

Sulfonamide derivatives

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.